Professor of Medicine
Pediatrics and Genetics
Director, Stanford Program for Clinical Cancer Genetics
Stanford University School of Medicine
Seeking to improve risk assessment in high-risk women and familie.
Studies are ongoing to identify disease-causing gene mutation from a high-risk family cancer registry database.
This research will improve current gene panel testing by assessing the risks associated with gene mutations in families with a high rate of breast cancer.
Currently available gene panel tests for assessing the genetic risk of breast cancer are uninformative for most patients, even those with strong family histories. Emerging technologies allow inexpensive sequencing of multiple genes, but we do not know whether these tests will improve patient care.
Dr. Ford and his team use high-throughput, multi-gene sequencing technology to identify risk-associated gene variants in many breast cancer-related genes. They recently reported that 10 percent of women with personal/family history of breast cancer carry a possible pathogenic gene variant, half in genes other than BRCA1/2, including ATM, CDH1, p53, PALB2, CHEK2, and Lynch syndrome genes.
In the coming year, they will determine if these are disease-causing gene mutations by assessing tumor gene mutations and family inheritance patternsin a population-based registry of breast cancer cases and healthy controls. They will also perform “liquid biopsy” analyses of circulating tumor DNA for early detection of cancer in high-risk individuals.
The results will have strong potential to guide the clinical use of emerging genetic tests to better inform patients about risk and preventive strategies.
Dr. Ford is a medical oncologist and geneticist at Stanford, devoted to studying the genetic basis of breast cancer development, treatment and prevention. He graduated from Yale where he received his MD in 1989. He trained clinically in Medicine and Oncology at Stanford followed by a research fellowship in Biological Sciences, and has been on the faculty at Stanford since 1998, currently as an Associate Professor of Medicine (Oncology), Pediatrics (Medical Genetics) and Genetics, and Director, Stanford Program for Clinical Cancer Genetics and Genomics.
Dr. Ford's goals are to understand the role of genetic changes in cancer genes in the risk and development of common cancers. He discovered that the p53 and BRCA1 tumor suppressor genes regulate DNA repair. He is using techniques for high-throughput genomic analyses of cancer to identify molecular signatures for targeted therapies, and whole-genome next-generation DNA sequencing to identify novel germline cancer susceptibility genes.
Dr. Ford's honors and awards include the Etta S. Chidsey Award in Cancer Research from Yale, NIH K08 Clinical Investigator Award, Second Annual Gerald B. Grindey Memorial Young Investigator Award - AACR, Sidney Kimmel Foundation for Cancer Research Scholar Award, Doris Duke Foundation Clinical Scientist Award in Cancer Etiology and Pathogenesis, Burroughs-Wellcome Fund New Investigator Award in Toxicology, and the V Foundation Translational Research Award. Dr. Ford is an Editor for the journal PLoS Genetics, is on the Scientific Review Committee for the V Foundation for Cancer Research, and former Council President of the California Breast Cancer Research Program.